Running summarizing tools on a new article
Check the paper below, then start its synthesis.
APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases
Hélène-Marie Lanoiselée (Inserm, Centre hospitalier universitaire d'Orléans), Gaël Nicolas (Inserm, Centre Hospitalier Universitaire de Rouen), David Wallon (Inserm, Centre Hospitalier Universitaire de Rouen), Anne Rovelet‐Lecrux (Inserm, Centre Hospitalier Universitaire de Rouen), Morgane Lacour (Inserm, Centre Hospitalier Universitaire de Rouen), Stéphane Rousseau (Inserm, Centre Hospitalier Universitaire de Rouen), Anne‐Claire Richard (Inserm, Centre Hospitalier Universitaire de Rouen), Florence Pasquier (Inserm, Université de Lille), Adeline Rollin‐Sillaire (Inserm, Université de Lille), Olivier Martinaud (Inserm, Centre Hospitalier Universitaire de Rouen), Muriel Quillard‐Muraine (Centre Hospitalier Universitaire de Rouen), Vincent de La Sayette (Centre Hospitalier Universitaire de Caen Normandie), Claire Boutoleau‐Bretonnière (Centre Hospitalier Universitaire de Nantes), Frédérique Etcharry‐Bouyx (Centre Hospitalier Universitaire d'Angers), Valérie Chauviré (Centre Hospitalier Universitaire d'Angers), Marie Sarazin (Centre Hospitalier Sainte-Anne), Isabelle Le Ber (Centre National de la Recherche Scientifique, Inserm), Stéphane Epelbaum (Centre National de la Recherche Scientifique, Inserm), Thérèse Jonveaux (Centre Hospitalier Régional et Universitaire de Nancy), Olivier Rouaud (CHU Dijon Bourgogne), Mathieu Pierre Ceccaldi (Inserm, Aix-Marseille Université), Olivier Félician (Inserm, Aix-Marseille Université), Olivier Godefroy (Centre Hospitalier Universitaire Amiens-Picardie, Laboratoire de neurosciences fonctionnelles et pathologies), Maïté Formaglio (Hospices Civils de Lyon), Bernard Croisile (Hospices Civils de Lyon), Sophie Auriacombe (Centre Hospitalier Universitaire de Bordeaux), Ludivine Chamard-Witkowski (Centre Hospitalier Universitaire de Besançon), Jean-Louis Vincent (Centre Hospitalier Universitaire de Lille), Mathilde Sauvée (Centre Hospitalier Universitaire de Grenoble), Cécilia Marelli (Centre Hospitalier Universitaire de Montpellier), Audrey Gabelle (Centre Hospitalier Universitaire de Montpellier), Canan Özsancak (Centre hospitalier universitaire d'Orléans), Jérémie Pariente (Centre Hospitalier Universitaire de Toulouse, Hôpital Purpan), Claire Paquet (Inserm, Assistance Publique – Hôpitaux de Paris), Didier Hannequin (Inserm, Centre Hospitalier Universitaire de Rouen), Dominique Campion (Inserm, Centre Hospitalier du Rouvray), collaborators of the CNR-MAJ project
Abstract: BACKGROUND: Amyloid protein precursor (APP), presenilin-1 (PSEN1), and presenilin-2 (PSEN2) mutations cause autosomal dominant forms of early-onset Alzheimer disease (AD-EOAD). Although these genes were identified in the 1990s, variant classification remains a challenge, highlighting the need to colligate mutations from large series. METHODS AND FINDINGS: We report here a novel update (2012-2016) of the genetic screening of the large AD-EOAD series ascertained across 28 French hospitals from 1993 onwards, bringing the total number of families with identified mutations to n = 170. Families were included when at least two first-degree relatives suffered from early-onset Alzheimer disease (EOAD) with an age of onset (AOO) ≤65 y in two generations. Furthermore, we also screened 129 sporadic cases of Alzheimer disease with an AOO below age 51 (44% males, mean AOO = 45 ± 2 y). APP, PSEN1, or PSEN2 mutations were identified in 53 novel AD-EOAD families. Of the 129 sporadic cases screened, 17 carried a PSEN1 mutation and 1 carried an APP duplication (13%). Parental DNA was available for 10 sporadic mutation carriers, allowing us to show that the mutation had occurred de novo in each case. Thirteen mutations (12 in PSEN1 and 1 in PSEN2) identified either in familial or in sporadic cases were previously unreported. Of the 53 mutation carriers with available cerebrospinal fluid (CSF) biomarkers, 46 (87%) had all three CSF biomarkers-total tau protein (Tau), phospho-tau protein (P-Tau), and amyloid β (Aβ)42-in abnormal ranges. No mutation carrier had the three biomarkers in normal ranges. One limitation of this study is the absence of functional assessment of the possibly and probably pathogenic variants, which should help their classification. CONCLUSIONS: Our findings suggest that a nonnegligible fraction of PSEN1 mutations occurs de novo, which is of high importance for genetic counseling, as PSEN1 mutational screening is currently performed in familial cases only. Among the 90 distinct mutations found in the whole sample of families and isolated cases, definite pathogenicity is currently established for only 77%, emphasizing the need to pursue the effort to classify variants.